



Exceptional Results Released On Additional Clinical Trial Data For Skin Care Company

FOR IMMEDIATE RELEASE

November 29, 2007

Contact: Trish Stack 208/863-2396 trish@epionce.com

BOISE, Idaho – Dr. Carl Thornfeldt, chief executive officer and founder of Episciences, Inc., today announced that the data from a recently completed clinical trial showed Epionce® Renewal Facial Lotion to be superior to leading skin care products Obagi® C Serum 20, Nov III and Grafa® Chitoshield. This is the 14th clinical trial showing statistically significant superiority over other leading products.

A human clinical trial conducted by Stephans and Associates documented a statistically significant superiority of the Epionce® Renewal Facial Lotion over Obagi® C Serum 20, Nov III and Grafa® Chitoshield against UVB induced erythema and edema. The study was done over eight days, with UVB applied daily for four days. On the fifth day maximum inflammation occurred and statistically significant decrease of erythema and edema indicates measurable anti-inflammatory effects.

“We are very pleased with the results from this most recent study, as it shows once again the efficacy of our product line.” said Dr. Thornfeldt. “I believe it is important that we are able to provide the consumer data proving that the product they are using truly works at making their skin healthy and beautiful.”

Erythema is a large abnormal redness of the skin caused by capillary congestion, while edema is swelling from excessive accumulation of watery fluid in cells, tissues, or serous cavities. Both are examples of severe inflammation of the skin. Obagi® C Serum 20, Nov III and Grafa® Chitoshield are all leading skin care products in Japan. Stephans and Associates is a leading independent research firm based in Dallas, Texas.

The Epionce® product line is currently being sold around the United States in medical spas and physician offices. Episciences, Inc. signed an agreement last year to begin selling the product line in Japan through Rohto Pharmaceutical Co., Ltd. Agreements were signed earlier this fall with Eden Aesthetics of Danbury, England and HYC of Hong Kong for distribution to the European market and Asian markets outside of Japan.

###

About Episciences, Inc:

Episciences, Inc, was founded in 2002 and is based in Boise, Idaho. Episciences, Inc, integrates twenty-plus years of research into the development of a highly effective cosmeceutical, non-prescription, dermatological product line. This breakthrough product has been proven effective by 13 independent clinical studies to reverse and prevent the effects of visible skin aging and certain common skin diseases. For more information, including summaries of our clinical trials, visit our website at www.epionce.com.